Small nucleic acid drugs: unveiling the grand curtain of a pharmaceutical revolution
On January 9, 2026, China’s small nucleic acid drug R&D company Ribobio listed in Hong Kong. It surged 29.38% at the open, and its self-developed GalNAc delivery technology became the focus of market attention. The listing bell at the Hong…
